Dragun Duska, Böhler Torsten, Nieminen-Kelhä Melina, Waiser Johannes, Schneider Wolfgang, Haller Hermann, Luft Friedrich C, Budde Klemens, Neumayer Hans-Hellmut
Department of Nephrology, Medical Faculty of the Charité Campus Mitte, Berlin, Germany.
Kidney Int. 2004 Mar;65(3):1076-83. doi: 10.1111/j.1523-1755.2004.00478.x.
A novel immunomodulator, FTY720, modulates lymphocyte migration to injured tissues via enhanced lymphocyte sequestration to secondary lymphoid organs. We tested whether or not single-dose FTY720 (0.5 mg/kg) pretreatment rescues renal grafts from post-transplant preservation/reperfusion injury.
Rat renal grafts were cold-preserved in University of Wisconsin (UW) solution for 4 hours and then transplanted into syngeneic or allogeneic recipients that received a single dose of FTY720 24 hours before transplantation. Flow cytometry analysis of peripheral blood and lymph nodes was performed to confirm the biologic effect of FTY720. Grafts were harvested after 24 hours. Renal sections were examined histologically and stained for intracellular adhesion molecule-1 (ICAM-1), vascular cellular adhesion molecule-1 (VCAM-1), platelet endothelial cellular adhesion molecule-1 (PECAM-1), major histocompatibility complex (MHC) class II, and inflammatory cells. Interleukin-1 (IL-1) production was determined in renal protein extracts.
FTY720 pretreatment significantly increased CD3+ T-cell sequestration to lymph nodes in the face of peripheral lymphopenia. Isografts and allografts from the FTY720-treated groups did not develop increased creatinine (0.55 +/- 0.12 in isografts and 0.62 +/- 0.08 mg/dL in allografts), compared with vehicle controls (2.28 +/- 0.20 in isografts and 2.24 +/- 0.18 mg/dL in allografts). Kidneys from FTY720-treated groups also showed lower acute tubular damage scores. Furthermore, FTY720 decreased neutrophil influx, although circulating neutrophils were unchanged. FTY720 also prevented postischemic IL-1 intragraft production not affecting infiltration with recipient ED-1+ macrophages and MHC class II-positive cells. Expression of ICAM-1, VCAM-1, and PECAM did not differ among groups.
FTY720 ameliorated morphologic and functional consequences of post-transplant reperfusion injury. Thus, FTY720-induced peripheral T-cell absence may influence intragraft IL-1 production and neutrophil infiltration, despite proadhesive endothelial properties. FTY720 may broaden the utility in renal transplantation as a pretreatment strategy against preservation/reperfusion injury.
新型免疫调节剂FTY720通过增强淋巴细胞在次级淋巴器官中的滞留来调节淋巴细胞向损伤组织的迁移。我们测试了单剂量FTY720(0.5mg/kg)预处理是否能使肾移植免受移植后保存/再灌注损伤。
大鼠肾移植在威斯康星大学(UW)溶液中冷保存4小时,然后移植到同基因或异基因受体中,这些受体在移植前24小时接受单剂量FTY720。对外周血和淋巴结进行流式细胞术分析以确认FTY720的生物学效应。24小时后取出移植物。对肾切片进行组织学检查,并对细胞间黏附分子-1(ICAM-1)、血管细胞黏附分子-1(VCAM-1)、血小板内皮细胞黏附分子-1(PECAM-1)、主要组织相容性复合体(MHC)II类和炎性细胞进行染色。测定肾蛋白提取物中白细胞介素-1(IL-1)的产生。
面对外周淋巴细胞减少,FTY720预处理显著增加了CD3+T细胞在淋巴结中的滞留。与载体对照组相比,FTY720治疗组的同基因移植和异基因移植肌酐均未升高(同基因移植为0.55±0.12,异基因移植为0.62±0.08mg/dL)(同基因移植为2.28±0.20,异基因移植为2.24±0.18mg/dL)。FTY720治疗组的肾脏急性肾小管损伤评分也较低。此外,尽管循环中性粒细胞未改变,但FTY720减少了中性粒细胞的流入。FTY720还可防止缺血后移植物内IL-1的产生,且不影响受体ED-1+巨噬细胞和MHC II类阳性细胞的浸润。各组间ICAM-1、VCAM-1和PECAM的表达无差异。
FTY720改善了移植后再灌注损伤的形态学和功能后果。因此,尽管具有促黏附的内皮特性,但FTY720诱导的外周T细胞缺失可能会影响移植物内IL-1的产生和中性粒细胞的浸润。FTY720作为一种针对保存/再灌注损伤的预处理策略,可能会拓宽其在肾移植中的应用。